Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Polycythemia Vera 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Thrombocythemia, Essential 5Carcinoma, Hepatocellular 4Neoplasms 3Melanoma 3Skin Neoplasms 2Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Solid Cancers 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm of Uncertain Malignant Potential 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis C 1Hepatitis B, Chronic 1Hemangiosarcoma 1Glioma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Cancers × peginterferon alfa-2a × Clear all
NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
158 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡